Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Labelled Comp Radiopharm. 2018 Mar 12;61(9):727–738. doi: 10.1002/jlcr.3605

Figure 2. Receptor occupancy.

Figure 2

89Zr-trastuzumab PET biodistribution in patients given 10 mg of 89Zr-trastuzumab (untreated) A), 50 mg 89Zr-trastuzumab during concurrent trastuzumab treatment B), and 10 mg 89Zr-trastuzumab during concurrent trastuzumab treatment C) show different clearance rates in the blood pool D), and should be considered when dosing patients in the clinic. This research was originally published at Clin Pharmacol Ther. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586–592. (reproduced with permission from Wiley © ref.45)